Remarkably, multivalency confers the capacity to selectively internalize in CXCR4-overexpressing (CXCR4+) cells, showing a dramatically high uptake in CXCR4+ cancer tissues that reaches around 80% of the injected dose (%ID), with negligible distribution in normal tissues [51,52]. The gene discussed is CXCR4; the disease is cancer.